Format

Send to

Choose Destination
Iran Biomed J. 2018 Nov;22(6):367-73. Epub 2018 Jun 3.

Up-Regulation of miR-21, miR-25, miR-93, and miR-106b in Gastric Cancer

Author information

1
Department of Medical Genetics, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
2
Department of Medical Laboratory Sciences, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
3
Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
4
Urogenital Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Abstract

Background:

Differential expression profile of microRNAs (miRNAs) could be a diagnosis signature for monitoring gastric cancer (GC) progression. In this study, we focus on the comparison of expression levels of miR-21, miR-25, miR-93, miR-106b, and miR-375 during the sequential pattern of GC development, including normal gastric, gastric dysplasia, and GC sample.

Methods:

We used SYBR Green-based quantitative-PCR to quantify miRNAs expression.

Results:

Our analysis revealed the increased expression levels of miR-21 (p = 0.034), miR-25 (p = 0.0003), miR-93 (p = 0.0406), and miR-106b (p = 0.023) in GC samples. In addition, GC patients with positive lymph node metastasis showed the up-regulation of miR-25, miR-93, and miR-106b (p < 0.05).

Conclusion:

Our findings suggested that the expression of miR-21, miR-25, miR-93, and miR-106b altered in GC, and some of them may be further investigated as biomarkers for GC early detection and prognosis prediction.

KEYWORDS:

Biomarkers; microRNAs; Stomach cancer

PMID:
29859516
PMCID:
PMC6305817
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Pasteur Institute of Iran Icon for PubMed Central
Loading ...
Support Center